Cite
Yang C, Loehn M, Jurczyk A, et al. Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets. Diabetes Metab Syndr Obes. 2015;8:387-98doi: 10.2147/DMSO.S87253.
Yang, C., Loehn, M., Jurczyk, A., Przewozniak, N., Leehy, L., Herrera, P. L., Shultz, L. D., Greiner, D. L., Harlan, D. M., & Bortell, R. (2015). Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets. Diabetes, metabolic syndrome and obesity : targets and therapy, 8387-98. https://doi.org/10.2147/DMSO.S87253
Yang, Chaoxing, et al. "Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 387-98. doi: https://doi.org/10.2147/DMSO.S87253
Yang C, Loehn M, Jurczyk A, Przewozniak N, Leehy L, Herrera PL, Shultz LD, Greiner DL, Harlan DM, Bortell R. Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets. Diabetes Metab Syndr Obes. 2015 Aug 20;8:387-98. doi: 10.2147/DMSO.S87253. eCollection 2015. PMID: 26316789; PMCID: PMC4548726.
Copy
Download .nbib